Critical Role of Nitric Oxide in the Modulation of Prepulse Inhibition in Swiss Mice

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 2013 Oct 9

PMID 24101156

Citations 9

Authors

Ana C Issy

Joao Francisco C Pedrazzi

Bruno H Yoneyama

Elaine A Del-Bel

Affiliations

Soon will be listed here.

Abstract

Rationale: Nitric oxide (NO) modulates the dopamine uptake and release processes and appears to be implicated in dopamine-related pathologies, such as schizophrenia. However, it is unclear whether there is excess or deficient NO synthesis in schizophrenia pathophysiology. Analyses of the intracellular pathways downstream of NO system activation have identified the cyclic nucleotide cyclic guanosine monophosphate (cGMP) as a possible target for drug development. Defects in the sensorimotor gating of the neural mechanism underlying the integration and processing of sensory information have been detected across species through prepulse inhibition (PPI).

Objectives: The aim of this study was to investigate the effects of NO/cGMP increase on sensorimotor gating modulation during dopamine hyperfunction.

Methods: Mice were treated with NO donors and subjected to the PPI test. Treatment with the NO donor sodium nitroprusside was preceded by pretreatment with a soluble guanylate cyclase (sGC) inhibitor. Additionally, the mice were treated with NO donors and phosphodiesterases inhibitors prior to amphetamine treatment.

Results: Pretreatment with the NO donors enhanced the PPI response and attenuated the amphetamine-disruptive effects on the PPI. The sGC inhibitor did not modify the sodium nitroprusside effects. Additionally, the cGMP increase induced by a specific phosphodiesterase inhibitor did not modify the amphetamine-disruptive effect.

Conclusions: This study provides the first demonstration that an increase in NO can improve the PPI response and block the amphetamine-disruptive effects on the PPI response. Our data are consistent with recent clinical results. However, these effects do not appear to be related to an increase in cGMP levels, and further investigation is thus required.

Citing Articles

The efficacy and safety of sodium nitroprusside in the treatment of schizophrenia: a meta-analysis.

Fei X, Li J, Wang S, Wang J, Guo C, Qisha R Front Psychiatry. 2023; 14:1271624.

PMID: 38025431 PMC: 10657871. DOI: 10.3389/fpsyt.2023.1271624.

The Nitric Oxide (NO) Donor Molsidomine Attenuates Memory Impairments Induced by the D1/D2 Dopaminergic Receptor Agonist Apomorphine in the Rat.

Vartzoka F, Ozenoglu E, Pitsikas N Molecules. 2023; 28(19).

PMID: 37836704 PMC: 10574075. DOI: 10.3390/molecules28196861.

Duration of Social Isolation Affects Production of Nitric Oxide in the Rat Brain.

Vrankova S, Galandakova Z, Benko J, Cebova M, Riecansky I, Pechanova O Int J Mol Sci. 2021; 22(19).

PMID: 34638682 PMC: 8509065. DOI: 10.3390/ijms221910340.

The Nitric Oxide (NO) Donor Sodium Nitroprusside (SNP) and Its Potential for the Schizophrenia Therapy: Lights and Shadows.

Zoupa E, Pitsikas N Molecules. 2021; 26(11).

PMID: 34073534 PMC: 8199342. DOI: 10.3390/molecules26113196.

Dopamine Receptor Blockade Attenuates Purinergic P2X4 Receptor-Mediated Prepulse Inhibition Deficits and Underlying Molecular Mechanisms.

Khoja S, Asatryan L, Jakowec M, Davies D Front Cell Neurosci. 2019; 13:331.

PMID: 31396053 PMC: 6664007. DOI: 10.3389/fncel.2019.00331.

References

Braff D, Geyer M, Swerdlow N . Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl). 2001; 156(2-3):234-58. DOI: 10.1007/s002130100810. View

Koch M . The neurobiology of startle. Prog Neurobiol. 1999; 59(2):107-28. DOI: 10.1016/s0301-0082(98)00098-7. View

Klamer D, Engel J, Svensson L . The nitric oxide synthase inhibitor, L-NAME, block phencyclidine-induced disruption of prepulse inhibition in mice. Psychopharmacology (Berl). 2001; 156(2-3):182-6. DOI: 10.1007/s002130100783. View

Klamer D, Engel J, Svensson L . The neuronal selective nitric oxide synthase inhibitor, Nomega-propyl-L-arginine, blocks the effects of phencyclidine on prepulse inhibition and locomotor activity in mice. Eur J Pharmacol. 2004; 503(1-3):103-7. DOI: 10.1016/j.ejphar.2004.09.042. View

De Lima T, Davis M . Involvement of cyclic AMP at the level of the nucleus reticularis pontis caudalis in the acoustic startle response. Brain Res. 1995; 700(1-2):59-69. DOI: 10.1016/0006-8993(95)00837-g. View

Siuciak J, Chapin D, Harms J, Lebel L, McCarthy S, Chambers L . Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis. Neuropharmacology. 2006; 51(2):386-96. DOI: 10.1016/j.neuropharm.2006.04.013. View

Bujas-Bobanovic M, Bird D, Robertson H, Dursun S . Blockade of phencyclidine-induced effects by a nitric oxide donor. Br J Pharmacol. 2000; 130(5):1005-12. PMC: 1572164. DOI: 10.1038/sj.bjp.0703406. View

Kanes S, Tokarczyk J, Siegel S, Bilker W, Abel T, Kelly M . Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity. Neuroscience. 2006; 144(1):239-46. PMC: 3313447. DOI: 10.1016/j.neuroscience.2006.09.026. View

Ramirez J, Garnica R, Boll M, Montes S, Rios C . Low concentration of nitrite and nitrate in the cerebrospinal fluid from schizophrenic patients: a pilot study. Schizophr Res. 2004; 68(2-3):357-61. DOI: 10.1016/S0920-9964(03)00070-7. View

10.

Wratten N, Memoli H, Huang Y, Dulencin A, Matteson P, Cornacchia M . Identification of a schizophrenia-associated functional noncoding variant in NOS1AP. Am J Psychiatry. 2009; 166(4):434-41. PMC: 3295829. DOI: 10.1176/appi.ajp.2008.08081266. View

11.

Braff D, Geyer M, Light G, Sprock J, Perry W, Cadenhead K . Impact of prepulse characteristics on the detection of sensorimotor gating deficits in schizophrenia. Schizophr Res. 2001; 49(1-2):171-8. DOI: 10.1016/s0920-9964(00)00139-0. View

12.

Rutten K, van Donkelaar E, Ferrington L, Blokland A, Bollen E, Steinbusch H . Phosphodiesterase inhibitors enhance object memory independent of cerebral blood flow and glucose utilization in rats. Neuropsychopharmacology. 2009; 34(8):1914-25. DOI: 10.1038/npp.2009.24. View

13.

Salum C, Raisman-Vozari R, Michel P, Gomes M, Mitkovski M, Ferrario J . Modulation of dopamine uptake by nitric oxide in cultured mesencephalic neurons. Brain Res. 2008; 1198:27-33. DOI: 10.1016/j.brainres.2007.12.054. View

14.

Amann L, Gandal M, Halene T, Ehrlichman R, White S, McCarren H . Mouse behavioral endophenotypes for schizophrenia. Brain Res Bull. 2010; 83(3-4):147-61. DOI: 10.1016/j.brainresbull.2010.04.008. View

15.

Coyle J . Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol. 2006; 26(4-6):365-84. PMC: 11881825. DOI: 10.1007/s10571-006-9062-8. View

16.

Kapur S, Seeman P . Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis. Am J Psychiatry. 2001; 158(3):360-9. DOI: 10.1176/appi.ajp.158.3.360. View

17.

Weber M, Breier M, Ko D, Thangaraj N, Marzan D, Swerdlow N . Evaluating the antipsychotic profile of the preferential PDE10A inhibitor, papaverine. Psychopharmacology (Berl). 2008; 203(4):723-35. PMC: 2748940. DOI: 10.1007/s00213-008-1419-x. View

18.

Karatinos J, Rosse R, Deutsch S . The nitric oxide pathway: potential implications for treatment of neuropsychiatric disorders. Clin Neuropharmacol. 1995; 18(6):482-99. View

19.

Kelly M, Stein J, Vecsey C, Favilla C, Yang X, Bizily S . Developmental etiology for neuroanatomical and cognitive deficits in mice overexpressing Galphas, a G-protein subunit genetically linked to schizophrenia. Mol Psychiatry. 2008; 14(4):398-415, 347. PMC: 3312743. DOI: 10.1038/mp.2008.124. View

20.

Bender A, Beavo J . Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev. 2006; 58(3):488-520. DOI: 10.1124/pr.58.3.5. View